In conclusion, our findings strongly suggest that the presence of the ERα36 receptor isoform in breast cancer cell lines can block TLR4/NFκB actions via an ERα36–GPER1 interaction, and that ERα36 antagonizes ERα66 transcriptional activity. This evidence concerns the gene GPER1 and breast carcinoma.